The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis

Arthritis and Rheumatism

Volumn 62, Issue 3, 2010, Pages 647-657

  Bondeson, Jan ^a   Blom, Arjen B ^b   Wainwright, Shane ^a   Hughes, Clare ^a   Caterson, Bruce ^a   Van Den Berg, Wim B ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CLODRONIC ACID; COLLAGENASE 3; ETANERCEPT; GELATINASE B; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; ENZYME SYNTHESIS; HUMAN; KNEE OSTEOARTHRITIS; MACROPHAGE ACTIVATION; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNOVITIS; SYNOVIUM;

ANIMALS; CYTOKINES; HUMANS; MACROPHAGES; OSTEOARTHRITIS; SYNOVITIS;

EID: 77649110175     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27290     Document Type: Review

References (77)

1. Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis: macrophages. Arthritis Res Ther 2007;9:224.
2. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19.
3. Pelletier JP, Roughley PJ, DiBattista JA, McCollum R, Martel-Pelletier J. Are cytokines involved in osteoarthritic pathophysiology? Semin Arthritis Rheum 1991;20 Suppl 2:12-25.
4. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999;40:1-11.
5. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis: an inflammatory disease: potential implication for the selection of new therapeutic targets [review]. Arthritis Rheum 2001;44:1237-47.
6. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005;64:1263-7.
7. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:2356-64.
8. Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002;10:595-601.
9. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870-5.
10. Bondeson J, Foxwell BM, Brennan FM, Feldmann M. A new approach to defining therapeutic targets: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium, but spares anti-inflammatory mediators. Proc Natl Acad Sci U S A 1999;96:5668-73.
11. Amos N, Lauder S, Evans A, Feldmann M, Bondeson J. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IκBα reveals that most, but not all, inhibitory and destructive mediators, are NFκB dependent. Rheumatology (Oxford) 2006;45:1201-9.
12. Blom AB, van den Berg WB. The synovium and its role in osteoarthritis. In: Bronner F, Farach-Carson MC, editors. Bone and osteoarthritis. Vol. 4. New York: Springer-Verlag; 2007. p. 65-79.
13. Goldring MB, Goldring SB. Osteoarthritis. J Cell Physiol 2007; 213:626-34.
14. Goldring MB, Otero M, Tsuchimochi K, Ijiri K, Li Y. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 2008;67 Suppl III:iii75-iii82.
15. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237-46.
16. Blom AB, van der Kraan PM, van den Berg WB. Cytokine targeting in osteoarthritis. Curr Drug Targets 2007;8:283-92.
17. Malemud CJ. Cytokines as therapeutic targets for osteoarthritis. BioDrugs 2004;18:23-35.
18. Abramson SB, Yaziki Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Delivery Rev 2006;58:212-25.
19. Pelletier JP, Martel-Pelletier J. New trends in the treatment of osteoarthritis. Semin Arthritis Rheum 2005;34:13-4.
20. Berenbaum F. The quest for the holy grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther 2007;9:111.
21. Qvist P, Bay-Jensen AC, Christiansen C, Dam BE, Pastoreau P, Karsdal MA. The disease modifying osteoarthritis drug (DMOAD): is it on the horizon? Pharmacol Res 2008;58:1-7.
22. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003;48:2173-7.
23. Foxwell BM, Browne KA, Bondeson J, Clarke CJ, de Martin R, Brennan FM, et al. Efficient adenoviral infection with IκBα reveals that macrophage TNFαproduction in rheumatoid arthritis is NF-κB dependent. Proc Natl Acad Sci U S A 1998;95:8211-5.
24. Bondeson J, Browne KA, Brennan FM, Foxwell BM, Feldmann M. Selective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: lipopolysaccharideinduced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is NFκB independent. J Immunol 1999;162: 2939-45.
25. Hayes AL, Smith C, Foxwell BM, Brennan FM. CD45-induced tumor necrosis factor α production in monocytes is phosphatidylinositol 3-kinase-dependent and nuclear factor κB-independent. J Biol Chem 1999;274:33455-61.
26. Brennan FM, Hayes AL, Ciesielski CJ, Green P, Foxwell BM, Feldmann M. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor κB pathways in tumor necrosis factor α production in rheumatoid arthritis. Arthritis Rheum 2002;46:31-41.
27. Andreakos E, Smith C, Kiriakidis S, Monaco C, de Martin R, Brennan FM, et al. Heterogeneous requirement of IκB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 2003;48:1901-12.
28. Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissue. Arthritis Res Ther 2007;9:R112.
29. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006;8:R187.
30. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFαantibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
31. Bondeson J, Wainwright S, Hughes C, Caterson B. The regulation of ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 2008;26:139-45.
32. Van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte LB, van den Berg WB. Degenerative knee joint lesions in mice after a single intra-articular collagenase injection: a new model of osteoarthritis. J Exp Pathol (Oxford) 1990;71:19-31.
33. Blom AB, van Lent PL, Holthuysen AE, van der Kraan PM, Roth J, van Rooijen N, et al. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage 2004;12:627-35.
34. Van Lent PL, Blom AB, van der Kraan P, Holthuysen AE, Vitters E, van Rooijen N, et al. Crucial role of synovial lining macrophages in the promotion of transforming growth factor β-mediated osteophyte formation. Arthritis Rheum 2004;50:103-11.
35. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum 2003;48:3442-51.
36. Blaney Davidson EN, van der Kraan PM, van den Berg WB. TGF-β and osteoarthritis. Osteoarthritis Cartilage 2007;15:597-604.
37. Yang X, Chen L, Xu XL, Li CL, Huang CF, Deng CX. TGF-β/ SMAD3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J Cell Biol 2001;153:35-46.
38. Van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-β injections. Osteoarthritis Cartilage 2000;8:25-33.
39. Blaney Davidson EN, Vitters EL, Blom AB, van den Berg WB, van der Kraan PM. Age-related changes in chondrocyte differentiation make cartilage prone to OA development. Osteoarthritis Cartilage 2008;16 Suppl 4:S14-5.
40. Blom AB, van Lent PL, Libregts S, Holthuysen AE, van der Kraan PM, van Rooijen N, et al. Crucial role of macrophages in matrix metalloproteinase- mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum 2007;56:147-57.
41. Marini S, Fasciglione GF, Monteleone G, Maiotti M, Tarantino U, Coletta G. A correlation between knee cartilage degradation observed by arthroscopy and synovial proteinases activity. Clin Biochem 2003;36:295-304.
42. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004;50:2547-58.
43. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005;434:644-8.
44. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;434:648-52.
45. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res 2004;22:742-50.
46. Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor: potential for pharmacological intervention. J Biol Chem 2000;275:40307-15.
47. Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM. Gene deletion of either interleukin-1β, interleukin-1β-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 2003;48:3452-63.
48. Glasson SS. In vivo osteoarthritis target validation utilizing genetically-modified mice. Curr Drug Targets 2007;8:367-76.
49. Hartmann C, Tabin CJ. Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton. Cell 2001;104:341-51.
50. Guo X, Day TF, Jiang X, Garrett-Beal L, Topol L, Yang Y. Wnt/β-catenin signaling is sufficient and necessary for synovial joint formation. Genes Dev 2004;18:2404-17.
51. Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007;26:227-39.
52. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis: mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009;11:221.
53. Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards WG, et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2009. E-pub ahead of print.
54. Loughlin J, Dowling B, Chapman K, Marcelline L, Mustafa Z, Southam L, et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci U S A 2004;101:9757-62.
55. Urano T, Shiraki M, Narusawa K, Usui T, Sasaki N, Hosoi T, et al. Q89R polymorphism in the LDL receptor-related protein 5 gene is associated with spinal osteoarthritis in postmenopausal Japanese women. Spine 2007;32:25-9.
56. Blom AB, Brockbank SM, van Lent PL, van Beuningen HM, Geurts J, Takahashi N, et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum 2009;60:501-12.
57. Urano T, Narusawa K, Shiraki M, Usui T, Sasaki N, Hosoi T, et al. Association of a single nucleotide polymorphism in the WISP-1 gene with spinal osteoarthritis in postmenopausal Japanese women. J Bone Miner Metab 2007;25:253-8.
58. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, et al. Synovial macrophage depletion with clodronatecontaining liposomes in rheumatoid arthritis. Arthritis Rheum 2000;43:1951-9.
59. Saklatvala J. Inflammatory signaling in cartilage: MAPK and NF-κB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets 2007;7:305-13.
60. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002;9:12-20.
61. Chen LX, Lin L, Wang HJ, Wei XL, Fu X, Zhang JY, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NFκB-specific siRNA. Osteoarthritis Cartilage 2008;16:174-84.
62. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20:879-96.
63. Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008;17:349-59.
64. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1βconverting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003;11:738-46.
65. Pavelka K, Trc T, Karpas K, Vitek P, Sedlackova M, Vlasakova V, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum 2007;56:4055-64.
66. Grunke M, Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis 2006;65:555-6.
67. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34:1323-7.
68. Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009;29:961-5.
69. Guler-Yuksel M, Kloppenburg M, Allaart CF, Watt I, Dijkmans BA, Huizinga TW, et al. Infliximab might be protective against progressive radiographic interphalangeal osteoarthritis. Osteoarthritis Cartilage 2008;16 Suppl 4:S228.
70. Chevalier X, Girardeau B, Conzorier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:1317-23.
71. Goupille P, Mulleman D, Chevalier X. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Arthritis Res Ther 2007;9:110.
72. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, double-blind, placebocontrolled study. Arthritis Care Res 2009;61:344-52.
73. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al, for the 2000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9.
74. Goupille P, Chevalier X, Valat JP, Garaud P, Perin F, LePape A. Macrophage targeting with Tc-99-labelled J001 for scintigraphic assessment of experimental osteoarthritis in the rabbit. Br J Rheumatol 1997;36:759-62.
75. Piscaer TM, Muller C, Mindt TL, Lubberts E, Stoop R, Verhaar JA, et al. Folate mediated imaging in experimental osteoarthritis using SPECT/CT. Osteoarthritis Cartilage 2008;16 Suppl 4:S27-8.
76. Piscaer TM, van Osch GJ, Verhaar JA, Weinans H. Imaging of experimental osteoarthritis in small animal models. Biorheology 2008;45:355-64.
77. Van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, et al. Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009;60:12-21.